OliX Moves Into Spotlight Amid Strong RNAi Interest, New Platform
Big Pharma Deals To Follow?
With recently secured platform technology and various programs now entering clinical trials, South Korean RNAi therapeutics company OliX Pharmaceuticals is hoping to reach multiple licensing deals by next year.
